Loading...
XSHE
003020
Market cap578mUSD
Oct 09, Last price  
17.30CNY
1D
2.00%
1Q
-7.68%
IPO
-20.20%
Name

Hefei Lifeon Pharmaceutical Co Ltd

Chart & performance

D1W1MN
XSHE:003020 chart
P/E
23.90
P/S
2.54
EPS
0.72
Div yield, %
3.44%
Shrs. gr., 5y
0.21%
Rev. gr., 5y
-7.33%
Revenues
1.55b
+2.33%
733,321,219877,719,728962,166,6031,028,167,9161,166,572,1751,424,581,0311,650,031,8511,894,291,4312,273,254,4762,579,340,2272,579,340,2261,900,789,1811,518,486,2841,553,801,538
Net income
165m
+2.86%
36,693,23947,023,70753,823,57267,462,53576,819,46491,664,143105,141,111135,116,129172,227,177209,248,610209,248,614226,672,723160,597,318165,194,999
CFO
213m
+7.77%
-7,957,40035,537,50092,048,90058,995,00011,323,89864,451,513149,299,646172,489,276158,702,671200,638,124203,674,981197,532,742212,885,217
Dividend
May 29, 20260.36 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hefei Lifeon Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a wide array of pharmaceutical goods. Its product portfolio encompasses active pharmaceutical ingredients (APIs) such as succimer, urea, paeonol, felodipine, doxazosin mesylate, zofenopril calcium, troxerutin, and sodium 2,3-dimercapto-1-propanesulfonate. The company also manufactures various medicinal preparations, including felodipine sustained-release tablets, doxazosin mesylate extended-release tablets, melbinum glipizide tablets, yiqihewei capsules, kunning granules, armillariella oral solution, paeonol ointment, urea and vitamin E cream, Kecuo Yintong gel, and Compound Golden Larch bark gel. Additionally, Hefei Lifeon Pharmaceutical supplies plant extracts like clove oil, evening primrose oil, herba clinopodii P.E, quercetin, and dihydroquercetin. Beyond its manufacturing operations, the company operates a retail chain for pharmaceuticals. Established in 2002, Hefei Lifeon Pharmaceutical Co., Ltd. is headquartered in Hefei, China.

Key people

Xiaojuan Deng
Vice Chairman of the Board · since 2023
Yi Liu
Chief Financial Officer · since 2025
Tianhe Dai
Deputy General Manager · since 2022
Shaobing Gou
Deputy General Manager · since 2025
Yong Zheng
Deputy General Manager · since 2025
Jun Xia
Deputy General Manager, Secretary of tjhe Board · since 2018
Junqu Ji
Chairman of the Board · since 2010
Tiecheng Ji
Deputy General Manager, Director · since 2025
Jinhua Li
Independent Director · since 2022
Jing Shi
Independent Director · since 2023
Morong Yang
Independent Director · since 2020
IPO date
Dec 15, 2020
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT